DE69431358D1 - Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien - Google Patents

Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

Info

Publication number
DE69431358D1
DE69431358D1 DE69431358T DE69431358T DE69431358D1 DE 69431358 D1 DE69431358 D1 DE 69431358D1 DE 69431358 T DE69431358 T DE 69431358T DE 69431358 T DE69431358 T DE 69431358T DE 69431358 D1 DE69431358 D1 DE 69431358D1
Authority
DE
Germany
Prior art keywords
adjuvants
compositions
enclosure
micro
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431358T
Other languages
English (en)
Other versions
DE69431358T2 (de
Inventor
L Cleland
Amy Lim
Frank Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69431358D1 publication Critical patent/DE69431358D1/de
Publication of DE69431358T2 publication Critical patent/DE69431358T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69431358T 1993-10-22 1994-10-13 Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien Expired - Lifetime DE69431358T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14134193A 1993-10-22 1993-10-22
US14333293A 1993-10-25 1993-10-25
PCT/US1994/011674 WO1995011008A2 (en) 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of adjuvants

Publications (2)

Publication Number Publication Date
DE69431358D1 true DE69431358D1 (de) 2002-10-17
DE69431358T2 DE69431358T2 (de) 2003-06-05

Family

ID=26839008

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431358T Expired - Lifetime DE69431358T2 (de) 1993-10-22 1994-10-13 Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

Country Status (9)

Country Link
EP (1) EP0724431B1 (de)
JP (1) JPH09504523A (de)
AT (1) ATE223702T1 (de)
AU (1) AU7979094A (de)
CA (1) CA2172507C (de)
DE (1) DE69431358T2 (de)
DK (1) DK0724431T3 (de)
ES (1) ES2182850T3 (de)
WO (1) WO1995011008A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686045B1 (de) * 1993-02-23 2000-11-15 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
CA2172508C (en) * 1993-10-22 2005-08-23 Jeffrey L. Cleland Method for preparing microspheres comprising a fluidized bed drying step
EP0998917A1 (de) * 1993-11-19 2000-05-10 Alkermes Controlled Therapeutics Inc. II Herstellung biologisch abbaubarer Mikropartikel, die einen biologisch aktiven Stoff enthalten
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
EP0817619A4 (de) * 1996-01-24 1999-02-03 Us Army Neue poly-(lactid/glycolid)-mikrosphären mit verzögerter freisetzung ohne initialstoss
DE69841708D1 (de) * 1997-02-06 2010-07-22 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
JP4601823B2 (ja) 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AU2841100A (en) * 2000-02-08 2001-08-20 Institute Of Materials Research And Engineering Biodegradable and biocompatible polymeric microspheres encapsulating (I)salmonella enteritidis(I)bacteria
ES2160089B1 (es) * 2000-03-15 2002-05-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos.
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60238471D1 (de) * 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2500014B1 (de) * 2007-06-06 2018-08-08 Debiopharm Research & Manufacturing SA Aus Mikropartikeln hergestellte, langsam freigesetzte pharmazeutische Zusammensetzung
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2244695A1 (de) * 2007-12-07 2010-11-03 Novartis AG Zusammensetzungen zur induktion von immunantworten
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2308478A1 (de) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Abgabesystem zur verzögerten Freisetzung von Calciumkanalblocker Arzneistoffen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤

Also Published As

Publication number Publication date
CA2172507C (en) 2008-12-02
DE69431358T2 (de) 2003-06-05
EP0724431A1 (de) 1996-08-07
JPH09504523A (ja) 1997-05-06
CA2172507A1 (en) 1995-04-27
ES2182850T3 (es) 2003-03-16
DK0724431T3 (da) 2003-01-06
EP0724431B1 (de) 2002-09-11
WO1995011008A2 (en) 1995-04-27
WO1995011008A3 (en) 1996-09-19
ATE223702T1 (de) 2002-09-15
AU7979094A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DK0585943T3 (da) Opløselige ligander for CD40
DE3774935D1 (de) Mikrokristallines schleifmittel und verfahren zur herstellung.
DK0975333T3 (da) Alginatgel med langvarig frigörelse
NO20005564L (no) Biodegraderbare alginatgeler med langvarig frigjörelse
DE68924132D1 (de) Halbleiterbauteil und Verfahren zur dessen Herstellung.
DE3484778D1 (de) Verfahren zur herstellung der bordetella-pertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin.
EA199900069A1 (ru) Вакцинная композиция против малярии
DK0384323T3 (da) Sammensætning og fremgangsmåde til forstærkning af en fiskevaccines virkning
DE68911571D1 (de) Verfahren zur Herstellung von Silikonschaum-Zusammensetzungen.
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE59206781D1 (de) Verfahren zur Herstellung von Isocyanaten und Aufarbeitung des Rückstandes
DE59204902D1 (de) Verfahren zur Herstellung von Diphenylaminen
DE59102357D1 (de) Verfahren zur Herstellung von Diphenylaminen.
DE69313297D1 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
DE68917817D1 (de) Verfahren zur Herstellung von vernetzten Polycarbonaten und Zusammensetzungen daraus.
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
DE59201217D1 (de) Verfahren zur Herstellung von Alpha-Omega-Aminoalkoholen.
DE69007895D1 (de) Verfahren zur Herstellung von N-alkylsubstituierten Aminophenolen.
DE3851541D1 (de) Propylen-äthylen-kopolymer-zusammensetzung und verfahren zur herstellung.
DK0804199T3 (da) Anvendelse af penciclovir til behandling af postherpetisk neuralgi
ATE152916T1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind

Legal Events

Date Code Title Description
8364 No opposition during term of opposition